Analysts credit the Oncobiota microbiome-driven liquid biopsy platform for identifyingthe “infinite potential” of using microbiome markers to diagnose cancer.March 29, 2023. SAN DIEGO, Calif.–Based on an independent team of expert’srigorous evaluation of a broad...
The OncobiotaLUNG assay is the first blood microbiome-driven liquid biopsy with proven effectiveness, including identifying cancer in its earliest stages Breakthrough device designation validates Micronoma’s aim to improve the current standard of care for patients...
December 14, 2022. SAN DIEGO, Calif.– Micronoma, the first biotech company offering early cancer detection using a microbiome-driven liquid biopsy platform, today announced that Sandrine Miller-Montgomery, Ph.D., Pharm.D., CEO and Co-founder of Micronoma will...
An international collaboration between the Weizmann Institute, UC San Diego, and Micronoma provides the most comprehensive characterization of fungi in cancer to date, discovering synergistic interactions with bacteria and furthering the role of mycobiome as an...
Todd Czerwinski will oversee the development and execution of market access, strategic partnerships and sales as the company rolls out its groundbreaking early cancer diagnosis platform SAN DIEGO, May 24, 2022 — Micronoma, the first cancer detection biotech company...
Microbiome-driven liquid biopsy company draws international recognition for using innovative technology to enable early cancer detection and improve chances of survival SAN DIEGO, Nov. 3, 2021 /PRNewswire/ — Micronoma, the first cancer detection biotech company...
